These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 35021980)
1. A Comprehensive Study of miRNAs in Parkinson's Disease: Diagnostics and Therapeutic Approaches. Owais S; Siddique YH CNS Neurol Disord Drug Targets; 2023; 22(3):353-380. PubMed ID: 35021980 [TBL] [Abstract][Full Text] [Related]
2. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model. Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355 [TBL] [Abstract][Full Text] [Related]
3. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052 [TBL] [Abstract][Full Text] [Related]
4. Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases. Dorostgou Z; Yadegar N; Dorostgou Z; Khorvash F; Vakili O J Neurosci Res; 2022 Sep; 100(9):1775-1790. PubMed ID: 35642104 [TBL] [Abstract][Full Text] [Related]
5. Targeting alpha-synuclein for the treatment of Parkinson's disease. Rohn TT CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467 [TBL] [Abstract][Full Text] [Related]
7. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies]. Orimo S Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627 [TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
9. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics. Javed H; Kamal MA; Ojha S CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease and microRNAs - Lessons from model organisms and human studies. Evans B; Furlong HA; de Lencastre A Exp Gerontol; 2021 Nov; 155():111585. PubMed ID: 34634413 [TBL] [Abstract][Full Text] [Related]
11. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease? Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978 [TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge. Miraglia F; Betti L; Palego L; Giannaccini G Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035 [TBL] [Abstract][Full Text] [Related]
13. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. Daher JP Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286 [TBL] [Abstract][Full Text] [Related]
14. Autophagy‑regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review). Ma Z; Liang H; Hu B; Cai S; Yan D Int J Mol Med; 2023 Jun; 51(6):. PubMed ID: 37144489 [TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336 [TBL] [Abstract][Full Text] [Related]
16. A Drosophila model of Parkinson's disease. Feany MB; Bender WW Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Lee VM; Trojanowski JQ Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225 [TBL] [Abstract][Full Text] [Related]
18. Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Parkinson's disease. Mohammed OA; Elballal MS; El-Husseiny AA; Khidr EG; El Tabaa MM; Elazazy O; Abd-Elmawla MA; Elesawy AE; Ibrahim HM; Abulsoud AI; El-Dakroury WA; Abdel Mageed SS; Elrebehy MA; Nomier Y; Abdel-Reheim MA; El-Husseiny HM; Mahmoud AMA; Saber S; Doghish AS Pathol Res Pract; 2024 Jan; 253():155023. PubMed ID: 38081104 [TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617 [TBL] [Abstract][Full Text] [Related]
20. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]